Martin Edwards, a senior partner of Novo Holdings A/S, has joined Verona Pharma Plc’s board of directors as a non-executive director. Novo holds 11.76% of Verona’s stock. Dr Edwards is also chair of the board of Vantia Therapeutics Ltd and a member of the boards of six other companies including F2G Ltd, which is developing anti-fungal therapies. He was chief executive of ReNeuron Holdings Plc, the cell therapy company, from 1998 to 2003.
Dr Edwards trained in physiology and medicine at the University of Manchester and is a member of the UK Royal College of Physicians. He holds an MBA degree from the University of Warwick, UK.
Verona announced the appointment on 21 March 2019.
Copyright 2019 Evernow Publishing